As reported, CavNOxin could attenuate total aortic plaque up to 70% in diabetic apolipoprotein E knockout (ApoE−/−) mice, a well-established model of experimental atherosclerosis, whereas mice lacking eNOS show resistance to CavNOxin treatment, suggesting endogenous eNOS activation can provide atheroprotection in diabetes (12). This evidence concerns the gene APOE and diabetes mellitus.